<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37627287</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Relationship of Fibroblast Growth Factor 23 Serum Levels with Disease Characteristics in Systemic Lupus Erythematosus Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1222</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13081222</ELocationID><Abstract><AbstractText>Fibroblast growth factor 23 (FGF23), a hormone secreted by osteocytes and osteoblasts, is a major regulator of vitamin D and phosphate homeostasis. FGF23 has been associated with the disturbance of mineral homeostasis, and with kidney and cardiovascular diseases. Systemic lupus erythematosus (SLE) is an autoimmune disorder that can affect virtually any organ. In the present work, we set out to analyze the relationship of FGF23 with the expression of SLE, including patterns of activity, damage, and severity. A total of 284 well-characterized patients with SLE were recruited. Activity (SLEDAI), severity (Katz), and damage index (SLICC-DI) scores were determined. The serum levels of FGF23 were also assessed. Multivariable linear regression analysis was performed to study the relationship between disease characteristics and FGF23. FGF23 and 25(OH) vitamin D were negatively correlated. Furthermore, prednisone use was associated with higher circulating FGF23 after an adjustment for confounding factors. SLICC-DI was related to higher serum levels of FGF23 after a multivariable analysis. However, when the SLICC-DI index items and domains were analyzed separately, apart from proteinuria &#x2265;3.5 gm/24 h, only the musculoskeletal domain, encompassing arthritis and osteoporosis, was significantly associated with higher serum levels of FGF23. In conclusion, an association is observed between elevated serum FGF23 levels and disease damage, particularly related to musculoskeletal complications and proteinuria, in patients with SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Cladera</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Bernal</LastName><ForeName>Fuensanta</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8597-1943</Identifier><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Gonz&#xe1;lez</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7600-5308</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quevedo-Abeledo</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-0398-9072</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Doctor Negr&#xed;n, 35010 Las Palmas de Gran Canaria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Rivero</LastName><ForeName>Agust&#xed;n F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-9712-6990</Identifier><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vera-Gonz&#xe1;lez</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Central Laboratory, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Gonz&#xe1;lez</LastName><ForeName>Candelaria</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4702-1840</Identifier><AffiliationInfo><Affiliation>Division of Internal Medicine, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of La Laguna (ULL), 38200 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nunes-Andrade</LastName><ForeName>Ana L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of La Laguna (ULL), 38200 Tenerife, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Mej&#xed;as</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0548-2689</Identifier><AffiliationInfo><Affiliation>Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Instituto de Investigaci&#xf3;n Sanitaria Marqu&#xe9;s de Valdecilla (IDIVAL), 39011 Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Gay</LastName><ForeName>Miguel &#xc1;</ForeName><Initials>M&#xc1;</Initials><Identifier Source="ORCID">0000-0002-7924-7406</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, 28015 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cantabria, 39011 Santander, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraz-Amaro</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0197-5267</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital Universitario de Canarias, 38320 Tenerife, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of La Laguna (ULL), 38200 Tenerife, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7Q7P4S7RRE</RegistryNumber><NameOfSubstance UI="D000089703">Fibroblast Growth Factor-23</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-16-2</RegistryNumber><NameOfSubstance UI="D014807">Vitamin D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000089703" MajorTopicYN="N">Fibroblast Growth Factor-23</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="Y">Arthritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014807" MajorTopicYN="N">Vitamin D</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">disease damage</Keyword><Keyword MajorTopicYN="N">fibroblast growth factor 23</Keyword><Keyword MajorTopicYN="N">musculoskeletal complications</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37627287</ArticleId><ArticleId IdType="pmc">PMC10452311</ArticleId><ArticleId IdType="doi">10.3390/biom13081222</ArticleId><ArticleId IdType="pii">biom13081222</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu S., Quarles L.D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 2007;18:1637&#x2013;1647. doi: 10.1681/ASN.2007010068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2007010068</ArticleId><ArticleId IdType="pubmed">17494882</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto K.I., Ito M., Tatsumi S., Kuwahata M., Segawa H. New aspect of renal phosphate reabsorption: The type IIc sodium-dependent phosphate transporter. Am. J. Nephrol. 2007;27:503&#x2013;515. doi: 10.1159/000107069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107069</ArticleId><ArticleId IdType="pubmed">17687185</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.R., McMahon L.P., Holt S.G. Fibroblast growth factor 23. Ann. Clin. Biochem. 2014;51:203&#x2013;227. doi: 10.1177/0004563213510708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0004563213510708</ArticleId><ArticleId IdType="pubmed">24269946</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra J., Buttar R.S., Kaur P., Kreimerman J., Melamed M.L. FGF-23 and Cardiovascular Disease: Review of Literature. Curr. Opin. Endocrinol. Diabetes Obes. 2016;23:423. doi: 10.1097/MED.0000000000000294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MED.0000000000000294</ArticleId><ArticleId IdType="pmc">PMC6936216</ArticleId><ArticleId IdType="pubmed">27652999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003;56:481&#x2013;490. doi: 10.1136/jcp.56.7.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.56.7.481</ArticleId><ArticleId IdType="pmc">PMC1769989</ArticleId><ArticleId IdType="pubmed">12835292</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Nagafuchi Y., Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021;11:928. doi: 10.3390/biom11070928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11070928</ArticleId><ArticleId IdType="pmc">PMC8301935</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Iba&#xf1;ez D., Urowltz M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Sanchez-Guerrero J., Urowitz M., Bacon P., Bombardieri S., Hanly J., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363&#x2013;369. doi: 10.1002/art.1780390303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M., Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2006;24:S99&#x2013;S104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17083771</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J.D., Senegal J.L., Rivest C., Goulet J.R., Rothfield N. A Simple Severity of Disease Index for Systemic Lupus Erythematosus. Lupus. 1993;2:119&#x2013;123. doi: 10.1177/096120339300200210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339300200210</ArticleId><ArticleId IdType="pubmed">8330033</ArticleId></ArticleIdList></Reference><Reference><Citation>Resende A.L., Elias R.M., Wolf M., Dos Reis L.M., Graciolli F.G., Santos G.D., Dias C.B., Jorgetti V., Woronik V., Moys&#xe9;s R.M. Serum levels of fibroblast growth factor 23 are elevated in patients with active Lupus nephritis. Cytokine. 2017;91:124&#x2013;127. doi: 10.1016/j.cyto.2016.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2016.12.022</ArticleId><ArticleId IdType="pubmed">28063327</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimazaki S., Kazukawa I., Yamammoto H., Mori K., Kihara M., Naruke Y., Minagawa M. Elevation of serum fibroblast growth factor 23 level in a pediatric patient with lupus nephritis. CEN Case Rep. 2022;11:50&#x2013;54. doi: 10.1007/s13730-021-00625-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13730-021-00625-7</ArticleId><ArticleId IdType="pmc">PMC8811100</ArticleId><ArticleId IdType="pubmed">34296353</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova T., Cai X., Lee J., Mehta R., Zhang X., Yang W., Nessel L., Anderson A.H., Lo J., Porter A., et al. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am. J. Kidney Dis. 2020;75:235&#x2013;244. doi: 10.1053/j.ajkd.2019.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2019.07.022</ArticleId><ArticleId IdType="pmc">PMC7012684</ArticleId><ArticleId IdType="pubmed">31668375</ArticleId></ArticleIdList></Reference><Reference><Citation>Isakova T., Wahl P., Vargas G.S., Guti&#xe9;rrez O.M., Scialla J., Xie H., Appleby D., Nessel L., Bellovich K., Chen J., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370&#x2013;1378. doi: 10.1038/ki.2011.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2011.47</ArticleId><ArticleId IdType="pmc">PMC3134393</ArticleId><ArticleId IdType="pubmed">21389978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.C., Chen W.S., Chang D.M., Tsao Y.P., Wu T.H., Chou C.T., Tsai C.Y. Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only. Osteoporosis Int. 2015;26:601&#x2013;610. doi: 10.1007/s00198-014-2910-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-014-2910-3</ArticleId><ArticleId IdType="pubmed">25270396</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Gonz&#xe1;lez C., G&#xf3;mez-Bernal F., Quevedo-Abeledo J.C., Ferrer-Moure C., Espelos&#xed;n-Ortega E., Gonz&#xe1;lez-Gay M.&#xc1;., Ferraz-Amaro I. Alpha-Klotho protein in systemic lupus erythematosus. Clin. Exp. Rheumatol. 2023;41:41&#x2013;47. doi: 10.55563/clinexprheumatol/salqon.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/salqon</ArticleId><ArticleId IdType="pubmed">35349421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>